{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:48Z","timestamp":1786119468599,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/yct.0b013e3181c1880e","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T02:53:38Z","timestamp":1270695218000},"page":"139-142","source":"Crossref","is-referenced-by-count":6,"title":["Safety of the Electroconvulsive Therapy-Ziprasidone Combination"],"prefix":"10.1097","volume":"26","author":[{"given":"Vasilios G.","family":"Masdrakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Florakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tzanoulinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Markatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Oulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1461145701002437","article-title":"Electroconvulsive therapy in the era of modern psychopharmacology.","volume":"4","author":"McCall","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"key":"R2-17-20210126","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1520-6394(2000)12:3<130::AID-DA4>3.0.CO;2-C","article-title":"Side effects of electroconvulsive therapy.","volume":"12","author":"Datto","year":"2000","journal-title":"Depress Anxiety"},{"key":"R3-17-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.yct.0000165500.60784.05","article-title":"The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia.","volume":"21","author":"Braga","year":"2005","journal-title":"J ECT"},{"key":"R4-17-20210126","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622970500395280","article-title":"The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy.","volume":"7","author":"Nothdurfter","year":"2006","journal-title":"World J Biol Psychiatry"},{"key":"R5-17-20210126","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00124509-200603000-00013","article-title":"Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis.","volume":"22","author":"Painuly","year":"2006","journal-title":"J ECT"},{"key":"R6-17-20210126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/YCO.0b013e328010e29b","article-title":"Atypical antipsychotics in the treatment of mood disorders.","volume":"20","author":"Jarema","year":"2007","journal-title":"Curr Opin Psychiatry"},{"key":"R7-17-20210126","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1017\/S1461145708009231","article-title":"Treatment of bipolar disorder: a systematic review of available data and clinical perspectives.","volume":"11","author":"Fountoulakis","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"R8-17-20210126","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(01)01188-8","article-title":"Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.","volume":"425","author":"Schmidt","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R9-17-20210126","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euroneuro.2006.11.007","article-title":"A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.","volume":"17","author":"Arango","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R10-17-20210126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eurpsy.2006.06.004","article-title":"Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.","volume":"22","author":"Kudla","year":"2007","journal-title":"Eur Psychiatry"},{"key":"R11-17-20210126","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.pnpbp.2007.06.008","article-title":"Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.","volume":"31","author":"Ratner","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R12-17-20210126","first-page":"66","article-title":"Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.","volume":"35","author":"Kelly","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"R13-17-20210126","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2165\/00003495-200262110-00006","article-title":"Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.","volume":"62","author":"Haddad","year":"2002","journal-title":"Drugs"},{"key":"R14-17-20210126","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00023210-200317060-00004","article-title":"Ziprasidone in the management of schizophrenia: the QT interval issue in context.","volume":"17","author":"Taylor","year":"2003","journal-title":"CNS Drugs"},{"key":"R15-17-20210126","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/0269881108093843","article-title":"The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.","volume":"23","author":"Eker","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R16-17-20210126","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1024122706337","article-title":"Antipsychotic drugs and QT interval prolongation.","volume":"74","author":"Zareba","year":"2003","journal-title":"Psychiatr Q"},{"key":"R17-17-20210126","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1017\/S1092852900017004","article-title":"Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.","volume":"13","author":"Simpson","year":"2008","journal-title":"CNS Spectr"},{"key":"R19-17-20210126","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00124509-200309000-00004","article-title":"Thyrotropin-releasing hormone administration does not affect seizure threshold during electroconvulsive therapy.","volume":"19","author":"Zervas","year":"2003","journal-title":"J ECT"},{"key":"R20-17-20210126","first-page":"138","article-title":"The 'half-age' stimulation strategy for ECT dosing.","volume":"12","author":"Petrides","year":"1996","journal-title":"Convuls Ther"},{"key":"R22-17-20210126","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00124509-200206000-00005","article-title":"Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.","volume":"18","author":"Tang","year":"2002","journal-title":"J ECT"},{"key":"R23-17-20210126","first-page":"385","article-title":"The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.","volume":"57","author":"Gazdag","year":"2004","journal-title":"Ideggyogy Sz"},{"key":"R24-17-20210126","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/01.WNF.0000220816.86478.84","article-title":"Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report.","volume":"29","author":"Tan","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R25-17-20210126","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/IJAMH.2005.17.2.187","article-title":"Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.","volume":"17","author":"Dew","year":"2005","journal-title":"Int J Adolesc Med Health"},{"key":"R26-17-20210126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/YCT.0b013e3181571c0e","article-title":"The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.","volume":"24","author":"Masdrakis","year":"2008","journal-title":"J ECT"},{"key":"R27-17-20210126","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00213-004-2082-5","article-title":"Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded assessment study.","volume":"178","author":"Brook","year":"2005","journal-title":"Psychopharmacology"},{"key":"R28-17-20210126","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.yic.0000182121.59296.70","article-title":"Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.","volume":"21","author":"Olie","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R29-17-20210126","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R30-17-20210126","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4088\/JCP.v65n0212","article-title":"Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.","volume":"65","author":"Papakostas","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"suppl 8","key":"R31-17-20210126","first-page":"13","article-title":"Use of atypical antipsychotics in refractory depression and anxiety.","volume":"66","author":"Nemeroff","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R32-17-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852900019842","article-title":"From clinical research to clinical practice: a 4-year review of ziprasidone.","volume":"10","author":"Nemeroff","year":"2005","journal-title":"CNS Spectr"},{"key":"R33-17-20210126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/JCP.0b013e31816745de","article-title":"High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes.","volume":"28","author":"Mech","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R34-17-20210126","first-page":"1","article-title":"Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.","volume":"19","author":"Lublin","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R35-17-20210126","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00131746-200407000-00003","article-title":"No significant QTc interval changes with high-dose ziprasidone: a case series.","volume":"10","author":"Levy","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"R36-17-20210126","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1592\/phco.2005.25.11.1660","article-title":"Ziprasidone overdose: cases recorded in the database of Pfizer-Spain and literature review.","volume":"25","author":"Gomez-Criado","year":"2005","journal-title":"Pharmacotherapy"}],"container-title":["The Journal of ECT"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124509-201006000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:56Z","timestamp":1786040036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124509-201006000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/yct.0b013e3181c1880e","relation":{},"ISSN":["1095-0680"],"issn-type":[{"value":"1095-0680","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}